Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of two new resources: Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions, and the Palliative Care Formulary, the expert source of drug information in palliative and hospice care.

Subscribe Publication Updates

Publication Updates

09 Feb
Stockley's Interactions Checker_logo
Stockley’s Interactions Checker February 2021 Update

New and updated interactions now available

For February, 469 new interactions have been added, and 2237 existing interactions have been updated.

09 Feb
Stockleys Drug Interactions_logo
Stockley’s Drug Interactions February 2021 Update

Stockley’s Drug Interactions update with new and revised monographs.

For this update, several sections have been completely re-validated and updated, including those on activated factor XA inhibitors, cranberry, dabigatran, ivacaftor and related drugs, statins, tetracyclines, and urinary antimuscarinics. In addition, 15 new tyrosine kinase inhibitors have been added. This update contains 92 new monographs, and 213 existing monographs have been updated.

09 Feb
Palliative Care Formulary February 2021 Update

This update contains 5 revised monographs.

The following monographs have been fully revised: Anaemia; Ferrous sulfate.

The following monographs have undergone minor revision: Depot corticosteroid injections; Quick Clinical Guide: Death rattle; Urinary antimuscarinics.

09 Feb
AHFS Drug Information logo
AHFS February 2021 Update

This update contains 3 new monographs and 7 revised monographs.

New monographs: Lumasiran Sodium; Berotralstat; Oliceridine Fumarate

Revised monographs: Montelukast; Brinzolamide; Brimonidine; Phentermine and Topiramate; Timolol; Betaxolol; Dorzolamide

09 Feb
Clarity’s Diagnosis and Treatment Guidance February 2021 Update

This update contains 7 significant changes, 24 minor changes and 1 new topic.

Significant Changes:
• Mastitis and breast abscess – reviewed. A literature search was conducted to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.

• Jaundice in adults – reviewed. A literature search was conducted to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.

• Jaundice in the newborn – reviewed. A literature search was conducted to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.

• Squint in children – reviewed. A literature search was conducted in December 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last version of this topic. No major changes to clinical recommendations have been made.

• Diabetes type 2 – reviewed. A literature search was conducted in November 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring to improve clarity and navigation. The recommendations have been updated in line with current literature. Information on the hyperglycaemic emergency complication of hyperosmolar hyperglycaemic state (HHS) has been added.

• Tennis elbow – reviewed. A literature search was conducted in November 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. There have been minor structural changes, and a recommendation not to use corticosteroids routinely for treating tennis elbow has been added to this topic.

• Anticoagulation – oral. A literature search was conducted in to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to clinical recommendations have been made. However, sections on monitoring people taking anticoagulants during the COVID-19 pandemic has been included, based on the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic [MHRA, 2020].

Minor Changes:
• Immunizations – seasonal influenza – minor update. Information added to reflect the authorization of the use of the recombinant quadrivalent vaccine (QIVr) in the 2020/2021 immunization programme.

• Neuropathic pain – drug treatment – minor update. Severe respiratory depression added as an adverse effect of pregabalin in line with updated manufacturer’s SPC.

• Generalized anxiety disorder – minor update. Severe respiratory depression added as an adverse effect of pregabalin in line with updated manufacturer’s SPC.

• Sciatica (lumbar radiculopathy) – minor update. Recommendations on offering neuropathic drugs at follow-up, and advising people with sciatica when to seek follow-up have been clarified.

• Boils, carbuncles, and staphylococcal carriage – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Bronchiectasis – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Cellulitis – acute – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Chest infections – adult – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Chlamydia – uncomplicated genital – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Cough – acute with chest signs in children – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Eczema – atopic – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Lacerations – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Leg ulcer – venous – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Olecranon bursitis – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Paronychia – acute – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Rosacea – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Sore throat – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Whitlow (staphylococcal and herpetic) – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Whooping cough – minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.

• Epilepsy – minor update. The safety profile of valproate in paediatrics has been updated in line with revised manufacturer’s SPC.

• Coronavirus – COVID-19 – minor update. Prevalence figures have been updated and information that a new more transmissible variant of COVID-19 emerged in December 2020 has been added to this topic, along with updated information on vaccine dose schedules.

• Contraception – combined hormonal methods – minor update. Recommendations on switching from the progestogen-only implant to combined hormonal contraception have been updated in line with the updated Faculty of Sexual and Reproductive Healthcare (FSRH) guideline Switching or starting methods of contraception.

• Hyperthyroidism – minor update. Hypersensitivity reactions added as an adverse effect of propylthiouracil in line with updated manufacturer’s SPC.

• Diverticular disease – minor update. The duration of antibiotic treatment for uncomplicated acute diverticulitis has been updated in line with the NICE guideline Diverticular disease: diagnosis and management.

New Topic:
• Mental health in students – this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.

09 Feb
British National Formulary logo
British National Formulary February 2021 Update

This update contains 20 significant changes and 2 new monographs.

Significant Changes:
• Andexanet alfa (Ondexxya®): avoid use of andexanet prior to heparinisation [MHRA/CHM advice].

• Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma [NICE guidance].

• Avatrombopag (Doptelet®) for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure [SMC guidance].

• Bempedoic acid (Nilemdo®) in adults with primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid-lowering therapies; or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contra-indicated [SMC guidance].

• Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura [NICE guidance].

• COVID-19: updated guidance.

• COVID-19 vaccine: new guidance in-line with Public Health England recommendations.

• Dimethyl fumarate (Tecfidera®): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia [MHRA/CHM advice].

• Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban [MHRA/CHM advice].

• Fingolimod (Gilenya®): updated advice about the risks of serious liver injury and herpes meningoencephalitis [MHRA/CHM advice].

• Immunisation schedule: updated National flu immunisation programme in-line with Public Health England recommendations.

• Influenza vaccine: updated guidance in-line with Public Health England recommendations.

• Liraglutide for managing overweight and obesity [NICE guidance].

• Methylprednisolone as sodium succinate (Solu-Medrone®) 40 mg powder and solvent for solution for injection: change from lactose-containing to a lactose-free formulation; risk of serious allergic reactions if formulations are confused [MHRA/CHM advice].

• Mexiletine (Namuscla®) for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders [SMC guidance].

• Quinolones (systemic and inhaled fluoroquinolones): small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk [MHRA/CHM advice] (advice in ciprofloxacin, delafloxacin, levofloxacin, moxifloxacin, ofloxacin; see example in ciprofloxacin).

• Rheumatoid arthritis: updated guidance on management.

• Upadacitinib for treating severe rheumatoid arthritis [NICE guidance].

• Venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) [SMC guidance].

• Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia [NICE guidance].

New Monographs:

• COVID-19 vaccine.

• Treprostinil.

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

View more